ArticleClinical lymphoma, myeloma & leukemia2015
Clinical features of patients with Philadelphia-negative myeloproliferative neoplasms complicated by portal hypertension.
Article in Clinical lymphoma, myeloma & leukemia, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Characteristic of Patients With Gastroesophageal Varices and Portal Cavernoma
Anticoagulation Treatment of Patients With Gastroesophageal Varices and JAK2 V617 Mutation
Who cites it
15 citing papers in PubMed, 29 citations in OpenAlex.
- Multicenter analysis of the use of transjugular intrahepatic portosystemic shunt for management of MPN-associated portal hypertension.American journal of hematology · 2017Trial
- Masked polycythemia vera presenting as non-cirrhotic portal hypertension with isolated gastric varices: a case report.BMC gastroenterology · 2026Article
- Obliteration of liver sinusoids through platelet aggregates associated to extramedullary haematopoiesis in myeloid neoplasms.Virchows Archiv : an international journal of pathology · 2025Article
- Navigating 'grey areas' and challenges during evaluation of transplant eligibility in specific myelofibrosis populations: a perspective on behalf of the Chronic Malignancies Working Party of the EBMT.Bone marrow transplantation · 2025Review
- Role of Portosystemic Shunt and Portal Vein Stent in Managing Portal Hypertension Due to Hematological Diseases.Cureus · 2024Article
- Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.International journal of molecular sciences · 2023Review
- Interventional Management of Portal Hypertension in Cancer Patients.Current oncology reports · 2022Review
- Innovative strategies to improve hematopoietic stem cell transplant outcomes in myelofibrosis.American journal of hematology · 2022Review
- Characteristics of myeloproliferative neoplasm-associated portal hypertension and endoscopic management of variceal bleeding.Therapeutic advances in chronic disease · 2022Article
- Jejunal variceal rupture in a patient with myelofibrosis: a case report.Clinical journal of gastroenterology · 2021Article
- Clinical characteristics of portal hypertension complicated by gastroesophageal varices in patients with myeloproliferative neoplasms.Clinical and molecular hepatology · 2020Article
- Article
- Splanchnic Vein Thrombosis in the Myeloproliferative Neoplasms.Current hematologic malignancy reports · 2018Review
- Clinical value of liver and spleen shear wave velocity in predicting the prognosis of patients with portal hypertension.World journal of gastroenterology · 2017Observational
- Distinct ways to perform a liver biopsy: The core technique setups and updated understanding of these modalities.Endoscopic ultrasoundReview
Corrections and comments
- Commented on by
Authors and funding
10 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundPortal hypertension has been reported to afflict 7% to 18% of patients with Philadelphia-negative MPNs, with complications of variceal bleeding and ascites. The clinical features and outcomes of these patients are unclear. PATIENTS AND
methodsIn this multicenter retrospective study, we evaluated the clinical features of 51 patients with MPNs complicated by PHTN.
resultsThe diagnosis of underlying MPN was most frequently PV (39%) and primary MF (35%), followed by post-PV MF (18%), ET (4%), and post-ET MF (4%). Frequency of Janus Kinase 2 V617F mutation appears as expected in the underlying MPN. Thrombosis within the splanchnic circulation was prevalent in patients with polycythemia compared with other MPNs (76% vs. 26%; P = .0007).
conclusionPV and MF patients have a greater incidence of PHTN in our population, with thrombosis contributing to PHTN development in PV patients. Patients with splanchnic circulation thrombosis are potential candidates for screening for PHTN. These data might be useful for developing screening strategies for early detection of PHTN in patients with MPN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.